Back to search
FDAFDA · Food and drugs·Recall number D-0371-2022

Norepinephrine Bitartrate Injection USP 4 mg/4 mL (1 mg/mL), 4 mL Single-Dose Vials, 10 vials per carton, Rx Only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0703-1153-03.

Published January 19, 2022 · Recall initiated: December 31, 2021

Summary

FDA records drug Class II recall D-0371-2022, published January 19, 2022 and initiated December 31, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 11,450 vials; Lot: Lot # 100020800, exp 07/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Methylprednisolone, TN Norepinephrine BItartrate - MS, OH
Lot
Lot # 100020800, exp 07/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Norepinephrine Bitartrate Injection USP 4 mg/4 mL (1 mg/mL), 4 mL Single-Dose Vials, 10 vials per carton, Rx Only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0703-1153-03. recalled?

Yes. FDA published recall D-0371-2022 on January 19, 2022. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter